[go: up one dir, main page]

PE20050552A1 - Composicion farmaceutica compuesta por acido nicotinico u otro agonista del receptor de acido nicotinico y un antagonista del receptor dp - Google Patents

Composicion farmaceutica compuesta por acido nicotinico u otro agonista del receptor de acido nicotinico y un antagonista del receptor dp

Info

Publication number
PE20050552A1
PE20050552A1 PE2004000463A PE2004000463A PE20050552A1 PE 20050552 A1 PE20050552 A1 PE 20050552A1 PE 2004000463 A PE2004000463 A PE 2004000463A PE 2004000463 A PE2004000463 A PE 2004000463A PE 20050552 A1 PE20050552 A1 PE 20050552A1
Authority
PE
Peru
Prior art keywords
nicotinic acid
receptor
pharmaceutical composition
acid
acetic
Prior art date
Application number
PE2004000463A
Other languages
English (en)
Inventor
Kang Cheng
M Gerard Water
Gary O'neill
Kathleen M Metters
Original Assignee
Merck & Co Inc
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050552(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc, Merck Frosst Canada Ltd filed Critical Merck & Co Inc
Publication of PE20050552A1 publication Critical patent/PE20050552A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA CONSTITUIDA POR: a) ACIDO NICOTINICO (ACIDO PIRIDINA-3-CARBOXILICO), SUS SALES U OTRO AGONISTA DEL RECEPTOR NICOTINICO EN COMBINACION CON b) UN ANTAGONISTA SELECTIVO DEL RECEPTOR DE PROSTAGLANDINA D2 DENOMINADO DP, SIENDO UN COMPUESTO SELECCIONADO: ACIDO [5-[(4-CLOROFENIL)TIO]-4-(METILSULFONIL)-6,7,8,9-TETRAHIDROPIRIDO[3,2-b]INDOLIZIN-6-IL]ACETICO, ACIDO [9-[(3,4-DICLOROFENIL)TIO]-1-ISOPROPIL-7,8-DIHIDRO-6H-PIRIDO[3,4-b]PIRROLIZIN-8-IL]ACETICO, ACIDO ((1R)-6-FLUORO-8-(METILSULFONIL)-9-{(1S)-1-[4-(TRIFLUOROMETIL)FENIL]ETIL}-2,3,4,9-TETRAHIDRO-1H-CARBAZOL-1-IL)ACETICO, ENTRE OTROS Y c) OPCIONALMENTE OTRO AGENTE ACTIVO COMO UN INHIBIDOR DE LA HMG REDUCTASA: SIMVASTATINA. ESTA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ATEROESCLEROSIS, DISLIPIDEMIAS Y AFECCIONES RELACIONADAS
PE2004000463A 2003-05-15 2004-05-06 Composicion farmaceutica compuesta por acido nicotinico u otro agonista del receptor de acido nicotinico y un antagonista del receptor dp PE20050552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
PE20050552A1 true PE20050552A1 (es) 2005-08-06

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000463A PE20050552A1 (es) 2003-05-15 2004-05-06 Composicion farmaceutica compuesta por acido nicotinico u otro agonista del receptor de acido nicotinico y un antagonista del receptor dp

Country Status (44)

Country Link
US (4) US20040229844A1 (es)
EP (3) EP2286816A1 (es)
JP (2) JP4637833B2 (es)
KR (2) KR100806008B1 (es)
CN (3) CN100441184C (es)
AR (1) AR041089A1 (es)
AU (2) AU2004240597B2 (es)
BR (1) BRPI0410273A (es)
CA (1) CA2525772C (es)
CL (1) CL2004001056A1 (es)
CO (1) CO5630034A2 (es)
CR (2) CR8047A (es)
CY (2) CY1109476T1 (es)
DE (1) DE602004022036D1 (es)
DK (2) DK1624871T3 (es)
DO (1) DOP2004000907A (es)
EA (2) EA009744B1 (es)
EC (1) ECSP056156A (es)
ES (2) ES2328148T3 (es)
GE (2) GEP20084569B (es)
GT (1) GT200400098A (es)
HN (1) HN2004000171A (es)
HR (2) HRP20090424T1 (es)
IL (1) IL171962A (es)
IS (1) IS2708B (es)
JO (1) JO2564B1 (es)
MA (1) MA27835A1 (es)
ME (1) MEP60108A (es)
MX (1) MXPA05012272A (es)
MY (1) MY140639A (es)
NO (1) NO20055957L (es)
NZ (2) NZ543399A (es)
PA (1) PA8603201A1 (es)
PE (1) PE20050552A1 (es)
PL (2) PL1624871T3 (es)
PT (2) PT2116244E (es)
RS (3) RS52731B (es)
SG (1) SG153667A1 (es)
SI (2) SI1624871T1 (es)
TN (1) TNSN05290A1 (es)
TW (2) TWI334354B (es)
UA (1) UA89615C2 (es)
WO (1) WO2004103370A1 (es)
ZA (1) ZA200508288B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144913B2 (en) * 2001-05-23 2006-12-05 Merck Frosst Canada & Co. Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
PT2801354T (pt) 2004-10-08 2017-06-05 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8165517B2 (en) * 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
JP2008530250A (ja) * 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
JP2008538277A (ja) * 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド 脂質関連障害の治療用の組成物および方法
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR20080016567A (ko) * 2005-05-17 2008-02-21 쉐링 코포레이션 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클
JP2009507791A (ja) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
EP1962835A2 (en) * 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
JP2009525961A (ja) * 2006-01-20 2009-07-16 シェーリング コーポレイション 異常脂質血症の処置のためのニコチン酸受容体アゴニストとしての複素環
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
EP2061792A2 (en) * 2006-09-15 2009-05-27 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
MX2009002918A (es) * 2006-09-15 2009-03-31 Schering Corp Derivados azetidinona y sus metodos de uso.
CN101528746A (zh) * 2006-09-15 2009-09-09 先灵公司 治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
MX2010012514A (es) * 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
US20110165239A1 (en) * 2008-09-24 2011-07-07 Laman Alani Pharmaceutical compositions of atorvastatin
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
CN103038228A (zh) 2010-03-16 2013-04-10 安万特药物公司 作为前列腺素d2受体拮抗剂的取代的嘧啶类化合物
JP2013522307A (ja) 2010-03-16 2013-06-13 アベンティス・ファーマスーティカルズ・インコーポレイテツド プロスタグランジンｄ２受容体アンタゴニストとしての置換ピリミジン
EP4420734A3 (en) 2015-02-13 2024-11-06 Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
WO1979000169A1 (en) 1977-09-30 1979-04-05 Rca Corp Television system scheduler
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0821587A4 (en) * 1995-04-19 1999-05-19 Lipoprotein Technologies Inc COMPOSITIONS, KITS AND METHODS FOR ADMINISTERING ANTILIPEMICS AND MEDICINES AGAINST PLATELET AGGREGATION
SK283552B6 (sk) 1995-10-31 2003-09-11 Schering Corporation 2-Azetidinóny substituované cukrovými zvyškami, farmaceutický prípravok, kombinovaný farmaceutický prípravok a ich použitie
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
PT814782E (pt) 1995-12-22 2003-04-30 Nissan Chemical Ind Ltd Composicao farmaceutica estabilizada com um agente basico
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
DE69837610T2 (de) * 1997-07-31 2008-01-03 Kos Life Sciences, Inc., Weston Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
RU2247722C2 (ru) * 1997-10-27 2005-03-10 Др. Редди`З Лабораториз Лимитед Производные арилкарбоновых кислот, способы их получения, фармацевтическая композиция на их основе, способы лечения и предупреждения различных заболеваний, промежуточные соединения и способы их получения
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
CN1130342C (zh) 1998-12-07 2003-12-10 先灵公司 β－丙内酰胺的合成方法
JP2002533411A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための組み合わせ
AU3382699A (en) 1999-04-05 2000-10-23 Schering Corporation Stereoselective microbial reduction for the preparation of - (4-fluorophenyl) - 3(r)-(3(s) - hydroxy-3 (4-fluorophenyl) propyl))-4(s) (4-hydroxyphenyl)-2-azetidinone
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
JP4292742B2 (ja) 2000-03-09 2009-07-08 小野薬品工業株式会社 インドール誘導体、その製造方法および用途
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
US20040254224A1 (en) 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
US7144913B2 (en) * 2001-05-23 2006-12-05 Merck Frosst Canada & Co. Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
EP1424335A4 (en) 2001-09-07 2005-11-16 Ono Pharmaceutical Co INDOLE DERIVATIVES
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es) 2002-03-19 2004-12-06 Ono Pharmaceutical Co Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
CN100402026C (zh) * 2002-06-03 2008-07-16 诺瓦提斯公司 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
GT200400098A (es) 2005-03-03
RS20050777A (sr) 2008-04-04
MA27835A1 (fr) 2006-04-03
CN102526735A (zh) 2012-07-04
SI1624871T1 (sl) 2009-12-31
NO20055957L (no) 2006-02-14
GEP20105025B (en) 2010-06-25
HK1092722A1 (zh) 2007-02-16
MEP60108A (en) 2011-05-10
HRP20090424T1 (en) 2009-09-30
CR9808A (es) 2008-07-29
RS52731B (sr) 2013-08-30
CL2004001056A1 (es) 2005-03-28
CR8047A (es) 2006-07-14
KR100806008B1 (ko) 2008-02-26
DE602004022036D1 (de) 2009-08-27
TWI341199B (en) 2011-05-01
DK1624871T3 (da) 2009-11-16
DK2116244T3 (da) 2012-11-26
US20040229844A1 (en) 2004-11-18
EA011895B1 (ru) 2009-06-30
SG153667A1 (en) 2009-07-29
ZA200508288B (en) 2008-08-27
EP1624871B1 (en) 2009-07-15
AU2004240597A1 (en) 2004-12-02
EP2116244A1 (en) 2009-11-11
MXPA05012272A (es) 2006-05-19
PT1624871E (pt) 2009-09-07
DOP2004000907A (es) 2004-11-30
IS2708B (is) 2011-01-15
TW200803844A (en) 2008-01-16
PT2116244E (pt) 2012-11-02
HN2004000171A (es) 2011-07-11
JO2564B1 (en) 2010-11-03
NZ543399A (en) 2009-02-28
JP4637833B2 (ja) 2011-02-23
US20110118292A1 (en) 2011-05-19
EP2116244B1 (en) 2012-08-08
ES2328148T3 (es) 2009-11-10
CN1787819A (zh) 2006-06-14
IL171962A0 (en) 2006-04-10
CN100441184C (zh) 2008-12-10
EP1624871A1 (en) 2006-02-15
EP2286816A1 (en) 2011-02-23
CO5630034A2 (es) 2006-04-28
IL171962A (en) 2012-06-28
CA2525772C (en) 2011-03-15
HRP20120818T1 (hr) 2012-11-30
CY1113342T1 (el) 2016-06-22
US20090233977A1 (en) 2009-09-17
RS20120499A1 (sr) 2013-08-30
KR20080003470A (ko) 2008-01-07
CN101559227B (zh) 2012-03-21
UA89615C2 (ru) 2010-02-25
JP2010077151A (ja) 2010-04-08
PA8603201A1 (es) 2005-02-04
IS8071A (is) 2005-10-13
PL2116244T3 (pl) 2013-01-31
WO2004103370A1 (en) 2004-12-02
PL1624871T3 (pl) 2009-12-31
CN101559227A (zh) 2009-10-21
EA009744B1 (ru) 2008-04-28
MY140639A (en) 2010-01-15
GEP20084569B (en) 2008-12-25
CA2525772A1 (en) 2004-12-02
RS20120498A1 (sr) 2013-08-30
KR100960749B1 (ko) 2010-06-01
JP2006526030A (ja) 2006-11-16
BRPI0410273A (pt) 2006-05-16
EA200702674A1 (ru) 2008-04-28
TWI334354B (en) 2010-12-11
TNSN05290A1 (en) 2007-07-10
CY1109476T1 (el) 2014-08-13
KR20060012617A (ko) 2006-02-08
AU2004240597B2 (en) 2011-01-06
EA200501817A1 (ru) 2006-06-30
AU2011200986A1 (en) 2011-03-31
SI2116244T1 (sl) 2012-12-31
ES2392743T3 (es) 2012-12-13
NZ572515A (en) 2010-07-30
US20100076002A1 (en) 2010-03-25
TW200503757A (en) 2005-02-01
AR041089A1 (es) 2005-05-04
ECSP056156A (es) 2006-04-19
AU2011200986B2 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
PE20050552A1 (es) Composicion farmaceutica compuesta por acido nicotinico u otro agonista del receptor de acido nicotinico y un antagonista del receptor dp
MX392313B (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
ES2171123B1 (es) Composiciones farmaceuticas que comprenden un acido pirimidin-5-il-(3r,5s)-3,5-dihidroxihept-6-emoico o una sal del mismo y una sal inorganica en que el cation es multivalente.
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
PE20170306A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
EA200800162A1 (ru) Новые фармацевтические композиции с замедленным высвобождением и способы их получения
DOP2006000170A (es) Nuevos derivados de espirocromanona
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
GT200800143A (es) Derivados de pirimidina utilizados como inhibidores de cinasa pi-3
WO2009028495A1 (ja) 真菌性皮膚炎用剤
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
PE20080370A1 (es) Derivados de quinazolinona como antagonistas de cgrp
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20110706A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
ATE554770T1 (de) Therapeutisches mittel gegen entzündliche darmerkrankungen
PE20142337A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
CL2007003120A1 (es) Uso de una cantidad terapeuticamente eficaz de compuestos derivados de acido carbamico sustituidos y otro agente activo, para el tratamiento de la depresion.
AR069223A1 (es) Combinacion antihelmintica
AR078120A1 (es) Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas
CL2009000896A1 (es) Compuestos derivados de 3-fenilpirazolo[5,1-b]tiazol sustituido; composicion farmaceutica; utiles en el tratamiento de la depresion, ansiedad, isquemia, apoplejia, hipertension, esquizofrenia, entre otras enfermedades.

Legal Events

Date Code Title Description
FC Refusal